TWST vs. SANA, VCEL, AMAM, CGON, INBX, RXRX, DNA, ADAP, KYMR, and VIR
Should you be buying Twist Bioscience stock or one of its competitors? The main competitors of Twist Bioscience include Sana Biotechnology (SANA), Vericel (VCEL), Ambrx Biopharma (AMAM), CG Oncology (CGON), Inhibrx (INBX), Recursion Pharmaceuticals (RXRX), Ginkgo Bioworks (DNA), Adaptimmune Therapeutics (ADAP), Kymera Therapeutics (KYMR), and Vir Biotechnology (VIR). These companies are all part of the "medical" sector.
Sana Biotechnology (NASDAQ:SANA) and Twist Bioscience (NASDAQ:TWST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk.
Sana Biotechnology currently has a consensus target price of $11.67, suggesting a potential upside of 30.94%. Twist Bioscience has a consensus target price of $37.40, suggesting a potential upside of 10.55%. Given Twist Bioscience's higher probable upside, research analysts clearly believe Sana Biotechnology is more favorable than Twist Bioscience.
Twist Bioscience received 73 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 55.26% of users gave Twist Bioscience an outperform vote while only 47.83% of users gave Sana Biotechnology an outperform vote.
Sana Biotechnology has a net margin of 0.00% compared to Sana Biotechnology's net margin of -78.44%. Sana Biotechnology's return on equity of -32.16% beat Twist Bioscience's return on equity.
In the previous week, Sana Biotechnology had 1 more articles in the media than Twist Bioscience. MarketBeat recorded 5 mentions for Sana Biotechnology and 4 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 0.60 beat Sana Biotechnology's score of 0.49 indicating that Sana Biotechnology is being referred to more favorably in the media.
68.4% of Sana Biotechnology shares are owned by institutional investors. 34.9% of Sana Biotechnology shares are owned by company insiders. Comparatively, 3.9% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Twist Bioscience has higher revenue and earnings than Sana Biotechnology. Twist Bioscience is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.
Sana Biotechnology has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500.
Summary
Twist Bioscience beats Sana Biotechnology on 9 of the 17 factors compared between the two stocks.
Get Twist Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Twist Bioscience Competitors List
Related Companies and Tools